Why the study?
Does cisplatin chemotherapy cause paroxysmal supraventricular tachycardia in patients with squamous cell lung carcinoma?
Does cisplatin chemotherapy cause paroxysmal supraventricular tachycardia in patients with squamous cell lung carcinoma?
Cisplatin chemotherapy may be associated with cardiotoxicity, specifically paroxysmal supraventricular tachycardia, particularly when combined with other agents like etoposide.
Suggests possible cisplatin-associated PSVT requiring monitoring; leaves open causal link in lung cancer chemotherapy.
Cardiotoxicity is rarely observed during cisplatin chemotherapy. A possible synergistic toxic effect of cisplatin with etoposide on cardiac electrical activity is discussed. A case of a 60-year-old woman with squamous cell lung carcinoma who developed paroxysmal supraventricular tachycardia during cisplatin chemotherapy is reported. The potential cardiotoxicity should be considered when cisplatin is combined with other cardiotoxic agents or used in patients with cardiac disease.
No takes yet. Share an insight, caveat, or question.
Canobbio et al. (1986) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: